US4732901A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Certain pyridyl, thienyl or furyl propenoic acids or esters having anti-inflammatory anti-allergic properties
Assignee: Beecham Group PLC
•
Filing: 1986-02-27
•
Granted: 1988-03-22
•
Expires: 2006-02-27
Abstract
Abstract Compounds of formula (I): ##STR1## in which R 1 is hydrogen or C 1-6 alkyl; R 2 is hydrogen or a group --CO 2 R 3 where R 3 is hydrogen or C 1-6 alkyl; n is an integer of from 2 to 12; X represents a double or triple bond, and each of A and B represents hydrogen when X is a double bond, or both A and B are absent when X is a triple bond; and ##STR2## represents an aromatic heterocyclic ring, are disclosed as inhibitors of 5-lipoxygenase.
Inventors
- 👤 Derek R. Buckle
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 16:53
CPC Classifications
C; C07; C07D; C07D207/00; C07D207/02; C07D207/30; C07D207/32; C07D207/33; C07D207/337; A; A61; A61P; A61P29/00; A61P37/00; A61P37/08; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/54; C07D213/55; C07D231/00; C07D231/02; C07D231/10; C07D231/12; C07D233/00; C07D233/54; C07D233/64; C07D239/00; C07D239/02; C07D239/24; C07D239/26; C07D241/00; C07D241/02; C07D241/10; C07D241/12; C07D261/00; C07D261/02; C07D261/06; C07D261/08; C07D263/00; C07D263/02; C07D263/30; C07D263/32; C07D277/00; C07D277/02; C07D277/20; C07D277/22; C07D277/30; C07D307/00; C07D307/02; C07D307/34; C07D307/38; C07D307/54; C07D333/00; C07D333/02; C07D333/04; C07D333/06; C07D333/24
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
42 words
A compound of the formula ##STR19## wherein R 1 is hydrogen or C 1 -C 6 alkyl; R 2 is hydrogen; n is an integer of from 2 to 12; ##STR20## represents pyridyl, thienyl or furyl or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
42 words
A compound of the formula ##STR19## wherein R 1 is hydrogen or C 1 -C 6 alkyl; R 2 is hydrogen; n is an integer of from 2 to 12; ##STR20## represents pyridyl, thienyl or furyl or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
17 words
A compound according to claim 1, in which n is an integer of from 4 to 12.
Claim 4
Dependent Claim
14 words
A compound according to claim 1 in the form of a pharmaceutically acceptable salt.
Claim 5
Dependent Claim
41 words
A compound according to claim 1 which is selected from the group consisting of: (E)3-[3-(1-tridecynyl)-4-pyridyl]prop-2-enoic acid; (E)3-[3-(1-tridecynyl)-2-furanyl]prop-2-enoic acid; (E-)3-[5-(1-Octynyl)-2-furanyl]prop-2-enoic acid; (E)-3-[3-(1-Octynyl)-2-furanyl]prop-2-enoic acid; (E)-3-[5-(1-Octynyl)-2-thienyl]prop-2-enoic acid; (E)-3-[4-(1-Octynyl)-2-thienyl]prop-2-enoic acid; (E)-3-[4-(1-Octynyl)-3-thienyl]prop-2-enoic acid; 3-[2-(1-Octynyl]-3-thiophene]prop-2-enoic acid; or a pharmaceutically acceptable salt or C 1-6 alkyl ester thereof.
Claim 6
Dependent Claim
16 words
A compound according to claim 1, wherein ##STR21## is substituted in the 1,2 or 1,3 positions.
Claim 7
Dependent Claim
14 words
A compound according to claim 1, wherein ##STR22## is substituted in the 1,2, positions.
Claim 8
Dependent Claim
10 words
A compound according to claim 1, wherein ##STR23## is furyl.
Claim 9
Dependent Claim
10 words
A compound 3-[3-(1-tridecynyl)-2-furanyl]prop-2-enoic acid or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
10 words
A compound 3-[3-(1-tridecynyl)-2-furanyl]prop-2-enoic acid or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
30 words
A pharmaceutical composition for treatment of allergic disorders comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
31 words
A method of treating allergic disorders in mammals which comprises administering to the sufferer an effective non-toxic amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
Claim 13
Dependent Claim
30 words
A pharmaceutical composition for treatment of inflammatory disorders comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Claim 14
Dependent Claim
31 words
A method of treating inflammatory disorders in mammals which comprises administering to the sufferer an effective non-toxic amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US4501893A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-03-22 | 1991-09-21 | 1992-03-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-03-22 | 1995-09-21 | 1996-03-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-03-22 | 1999-09-21 | 2000-03-22 | $7700.00 | Window Closed / Lapsed |